Damaira Pharmaceuticals

What Damaira Pharmaceuticals does

Damaira Pharmaceuticals Pvt. Ltd. is a private Indian pharmaceutical manufacturer founded in 2020 and headquartered in Panchkula, Haryana, India. The company operates a dedicated, single-therapy manufacturing facility focused exclusively on Carbapenem-class dry powder injections — last-resort antibiotics used to treat severe and multi-resistant bacterial infections. Its commercial portfolio spans five molecules (Meropenem, Imipenem Cilastatin, Doripenem, Ertapenem, and Biapenem) offered across multiple strengths.

The facility is engineered for regulated-market compliance: production runs inside a Closed Restricted Access Barrier System (cRABS), is monitored via SCADA and 200+ sensors, and operates under 21 CFR Part 11 compliant software covering vial washing, sterilization, filling, stoppering, sealing, and QC instruments (HPLC, GC-HS, UV-Vis, FTIR, Total Organic Carbon analyzers, liquid-borne particle counters, incubators, and precision balances). Quality assurance is enforced through documented SOPs and continuous monitoring rather than through AI/ML-driven process optimization.

Damaira generates revenue through B2B institutional sales of its Carbapenem dry powder injections to hospitals, clinics, and pharmaceutical distributors in India. Pricing is negotiated through institutional procurement rather than publicly disclosed. The company received ₹6.25 crore in anchor equity from Astonea Labs, which has since been disclosed as a parent/strategic investor; the same investor has also established a US subsidiary (Astonea LLC), suggesting potential international commercial intent. Founder and Managing Director Vikul Bansal leads the 51-100 employee organization.

Name

Damaira Pharmaceuticals

Legal name

Damaira Pharmaceuticals Pvt. Ltd.

Website

https://damaira.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

Damaira Pharmaceuticals is a private Indian manufacturer dedicated to producing Carbapenem-class dry powder antibiotic injections for hospitals, clinics, and pharmaceutical distributors in India and select international markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules) (IMALAIAA)

Keywords

• Pharmaceutical manufacturing
• Carbapenem antibiotics
• Dry powder injections
• Sterile injectables
• Antibiotic production

Headquarters

HQ city

Haryana

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Carbapenem Dry Powder Injection Sales: Manufacturing and sale of Carbapenem class of antibiotics including Meropenem, Imipenem Cilastatin, Doripenem, Ertapenem, and Biapenem dry powder injections for injection. Revenue generated through product sales to healthcare providers and pharmaceutical distributors.

Distribution channels1 record

Marketing channels2 records

Core offering

Damaira Pharmaceuticals operates a dedicated manufacturing facility for Carbapenem-class Dry Powder Injections — a group of last-resort antibiotics used to treat severe and multi-resistant bacterial infections. The company produces five Carbapenem drugs (Meropenem, Imipenem Cilastatin, Doripenem, Ertapenem, and Biapenem) at multiple dosage strengths in a regulatory-compliant facility designed for international regulated market standards.

Product overview

Damaira Pharmaceuticals operates as a single-product focused manufacturer producing Carbapenem Dry Powder Injections, a class of last-resort antibiotics used for treating severe and multi-resistant bacterial infections. The company's product portfolio consists of five carbapenem antibiotics: Meropenem (available in 1000 mg, 500 mg, 250 mg, and 125 mg), Imipenem Cilastatin (available in 1000 mg + 1000 mg, 500 mg + 500 mg, and 250 mg + 250 mg combinations), Doripenem (500 mg and 250 mg), Ertapenem (1000 mg), and Biapenem (300 mg). The products are manufactured in a regulatory-compliant facility equipped with Closed Restricted Access Barrier System (cRABS) and 21 CFR Part 11 compliant monitoring systems, with a focus on delivering high-quality life-saving medicines at affordable costs.

Differentiator

Problem solved

Functional benefit

Products and services

• Meropenem Carbapenem-class broad-spectrum antibiotic dry powder for solution for injection, indicated for treating pneumonia, urinary tract infections, intra-abdominal infections, gynecological infections, skin infections, meningitis, and septicemia, including empiric treatment for febrile neutropenia. Available in 1000 mg, 500 mg, 250 mg, and 125 mg strengths.
• Imipenem Cilastatin Broad-spectrum beta-lactam antibiotic combining Imipenem (thienamycin class) with Cilastatin Sodium (renal dehydropeptidase inhibitor). Indicated for lower respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecological infections, bacterial septicemia, bone and joint infections, skin infections, endocarditis, and polymicrobic infections. Available in 1000 mg + 1000 mg, 500 mg + 500 mg, and 250 mg + 250 mg strengths.
• Doripenem Carbapenem-class antibiotic dry powder for injection used for treating severe bacterial infections. Available in 500 mg and 250 mg strengths.
• Ertapenem Carbapenem-class antibiotic dry powder for injection used as last-resort treatment for severe bacterial infections. Available in 1000 mg strength.
• Biapenem Carbapenem-class antibiotic dry powder for injection used for treating severe bacterial infections. Available in 300 mg strength.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Cipla: Major Indian generic manufacturer with a hospital-care division that includes injectable antibiotics. Comparable as a broad incumbent serving hospitals and distributors across the same Carbapenem therapeutic category.
• Alkem Laboratories: Indian generic pharmaceutical company with a dedicated Carbapenem injectable portfolio and active domestic and export sales. Comparable as a broad-line Indian competitor in the same Carbapenem FDF category.
• Glenmark Pharmaceuticals: Indian pharmaceutical manufacturer with an injectable portfolio serving Indian hospitals and distributors. Comparable as a domestic incumbent in the generic injectable antibiotics and hospital-care category.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company with a sterile injectable product line including Carbapenems. Comparable as a broad incumbent operating in the same domestic generic injectable space at far greater scale and distribution depth.
• Aurobindo Pharma: One of India's largest generic pharmaceutical manufacturers with a substantial sterile injectable portfolio including Carbapenems (Meropenem, Imipenem Cilastatin). Comparable as a domestic Indian supplier of Carbapenem finished dosage forms at significantly greater scale.
• Emcure Pharmaceuticals: Indian pharmaceutical company with a notable Carbapenem franchise and broader injectable portfolio. Comparable as a larger domestic player competing in Carbapenem dry powder injectable manufacturing and distribution.
• Strides Pharma: Indian specialty pharmaceutical manufacturer with a strong sterile injectable and oral dosage franchise serving global regulated markets. Comparable as a broader Indian sterile-injectable competitor with established export operations.

Direct peers

• Orchid Pharma: Indian pharmaceutical company with sterile injectable manufacturing capabilities including beta-lactam antibiotics. Comparable as a domestic Indian specialist in hospital injectables targeting similar institutional buyer segments.
• Venus Remedies: Indian pharmaceutical manufacturer with a focused Carbapenem (Meropenem, Imipenem Cilastatin, Ertapenem) and critical-care injectable franchise. Direct peer due to nearly identical product positioning in the Carbapenem dry powder injectable category.
• United Biotech: Focused Indian specialty pharmaceutical manufacturer with a Carbapenem-centered product portfolio (Meropenem, Imipenem Cilastatin, Ertapenem). Closest direct peer in terms of product mix, therapeutic focus, and scale of operations.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/damairapharma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Damaira Pharmaceuticals